Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Bad financial results growth rate -11.2% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-1.7%)
  • Dividend yield for the last twelve months 7.7%
  • Free cash flow yield 10.3% (LTM)
  • Share price is 2.0% higher than minimum and 59.6% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (11.8x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.1 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (-3.7%)22.02
year average price 26.99  


year start price 28.92 2024-05-16

max close price 31.39 2024-07-30

min close price 21.59 2025-04-10

current price 22.02 2025-05-15
Common stocks: 5 615 000 000

Dividend Yield:  7.7%
FCF Yield LTM: 10.3%
EV / LTM EBITDA: 11.8x
EV / EBITDA annualized: 9.6x
Last revenue growth (y/y):  -7.8%
Last growth of EBITDA (y/y):  -14.6%
Historical revenue growth:  -7.3%
Historical growth of EBITDA:  +3.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 123 642
Net Debt ($m): 45 091
EV (Enterprise Value): 168 733
EBITDA LTM ($m): 14 282
EV / LTM EBITDA: 11.8x
Price to Book: 1.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-14reuters.com

EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer

2025-05-12fool.com

Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.

2025-05-06seekingalpha.com

Pfizer Has Unreasonable Whiff Of The Marlboro Man

2025-05-05zacks.com

Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?

2025-05-02247wallst.com

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025)

2025-05-02fool.com

3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May

2025-05-01zacks.com

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

2025-04-30fool.com

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

2025-04-30seekingalpha.com

Pfizer's Q1 Update May Mark A Bottom In The Stock

2025-04-30fool.com

Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data